Who is sponsoring START-NET?

START-NET is sponsored by Lund University Hospital.

What condition does START-NET study?

START-NET studies Neuroendocrine Tumors.

What drugs are being tested in START-NET?

Interventions: 177Lu-DOTATOC, Capecitabine.

What is the status of START-NET?

START-NET is currently RECRUITING.

Last reviewed 2025-09-10 · How we verify

Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors. (START-NET)

NCT05387603 PHASE3 RECRUITING

There are several ways of personalizing PRRT (peptide receptor radionuclide treatment) in NEN (neuroendocrine neoplasia). Nevertheless, the current treatment regimen is not personalized. This trial aims to compare personalized PRRT to non-personalized PRRT in terms of safety, efficacy and resource demands in order to optimize treatment outcomes in an evidence-based manner in future.

Details

Lead sponsor	Lund University Hospital
Phase	PHASE3
Status	RECRUITING
Enrolment	300
Start date	Tue Nov 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Oct 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Neuroendocrine Tumors

Interventions

177Lu-DOTATOC
Capecitabine

Countries

Sweden